IJPHT Journal
Papers Having Good Impact

International Journal of Pharmacy and Herbal Technology (Online)

Home Page: https://www.ijprdjournal.com/

MOLECULAR DOCKING OF ANTIVIRAL ACTIVITY ON PYRIMIDINE DERIVATIVES

Dheeraj D. Dhane,* Sriniwas R. Mane, Sanjay K. Bais
Fabtech College of Pharmacy, Sangola
Tal-Sangola, Dist.-Solapur
Maharashtra -413307

ABSTRACT

The ongoing search for effective antiviral agents has led to the exploration of various chemical compounds, with pyrimidine derivatives emerging as promising candidates due to their broad- spectrum antiviral activities. This study focuses on the molecular docking of a series of pyrimidine derivatives to evaluate their potential as antiviral agents. Utilizing advanced computational techniques, we performed molecular docking simulations In order to forecast these compounds' binding affinities and patterns of interaction with important viral proteins including proteases and polymerases, which are crucial for viral replication.

Our findings underscore the significance of pyrimidine derivatives as a scaffold for the development of novel antiviral drugs. The high binding affinities observed in this study warrant further experimental validation and optimization of these compounds. This research not only contributes to the identification of potential antiviral agents but also enhances the understanding of molecular interactions that govern antiviral activity, paving the way for the rational design of more potent antiviral therapeutics.

Keywords: *Pyrimidine derivatives, antiviral agents, molecular docking, structure-activity relationship*

*Corresponding Author Email: - dheerajdhane333@gmail.com
Received on 06 July, 2024, Accepted 15 July, 2024

Please cite this article as: Dhane Dheeraj et. Molecular Docking of Antiviral Activity on Pyrimidine Derivatives
International Journal of Pharmacy And Herbal Technology 2024.

INTRODUCTION

This process is essential in drug discovery and development, as it helps understand Hydrophobic contacts as well as hydrogen bonds are considered critical interactions. . The effectiveness of molecular docking lies in its ability to simulate and visualize the binding of small molecules (ligands) to large biomolecules (proteins), providing insights into the structural and functional relationships governing these interactions.[1] he continuous threat posed by viral infections necessitates the development of effective antiviral agents. Traditional drug discovery processes often face challenges such as long development times and high costs. To address these issues, computational approaches like molecular docking have become invaluable tools facilitating for the swiftly screening and identification among potential therapeutic compounds in the first stages of drug discovery.[2]

Among various chemical scaffolds, pyrimidine derivatives have garnered significant attention due to their diverse biological activities, including potent antiviral effects.[3]

Pyrimidines are heterocyclic aromatic organic compounds that form the core structure of several nucleotides, the building blocks of DNA and RNA. This inherent biological relevance, combined with their chemical versatility, makes pyrimidine derivatives promising candidates for antiviral drug development. These compounds can be designed to interact with various viral targets, disrupting critical processes in the viral life cycle, such as replication, transcription, and protein processing.[4]

Molecular docking studies offer a robust platform for predicting the interactions between pyrimidine derivatives and viral proteins. By simulating the binding of these compounds to key viral enzymes and structural proteins, researchers can gain insights into their binding affinities and modes of action. This computational technique helps identify promising lead compounds and guides subsequent experimental validation and optimization.[5]

In this study, we focus on the molecular docking of pyrimidine derivatives with essential viral proteins, aiming to identify potential antiviral agents and elucidate the structural features that contribute to their efficacy. By exploring the interactions of these compounds with targets such as HIV-1 protease, HCV NS5B RNA polymerase, and SARS-CoV-2 main protease, we aim to uncover new avenues for the development of effective antiviral therapies. This research not only enhances our understanding of the antiviral potential of pyrimidine derivatives but also provides a foundation for the rational design of novel antiviral drugs.[6]

METHODOLOGY

Library Compilation

A diverse library of pyrimidine derivatives will be compiled from chemical databases such as PubChem, ChEMBL, and proprietary compound libraries. Selection criteria will include structural diversity, reported biological activities, and drug-like properties.[7]

Target Protein Selection

Viral Proteins

Key viral proteins essential for the replication and life cycle of various viruses will be selected as docking targets. These include:

HIV-1 Protease: Involved in the maturation of HIV particles.[8]

NS5B RNA Polymerase of HCV: Crucial for RNA synthesis in Hepatitis C Virus.

SARS-CoV-2 Main Protease (Mpro): Responsible for processing viral polyproteins in the novel coronavirus.

Protein Preparation

Structure Retrieval

Crystal structures of the selected viral proteins will be obtained from the Protein Data Bank (PDB).[9]

Preparation

Tools include Schrödinger's Protein Preparation Wizard & AutoDockTools will be employed for creating protein structures. This involves adding the missing atoms, determining the appropriate bond order, and hydrogen bond efficiency.[10]

Ligand Preparation

Structure Optimization: Pyrimidine derivatives will be optimized using computational chemistry tools to minimize energy and ensure proper 3D conformations.

Parameter Assignment: Appropriate force field parameters and partial charges will be assigned to the ligands using software such as AutoDockTools or OpenBabel.

Molecular Docking Simulations

Docking Software: Molecular docking will be performed using software like AutoDock Vina, Schrödinger's Glide, or GOLD.

Grid Definition: The active site of each viral protein will be defined to create a docking grid, focusing on regions critical for enzyme activity or substrate binding.

Docking Runs: Each pyrimidine derivative will be docked into the active site of each viral protein. Multiple docking runs will be performed to ensure reliability and reproducibility of the results.[11]

Analysis of Docking Results

Binding Affinity Assessment: Docking scores will be analysed to evaluate the binding affinities of pyrimidine derivatives to the target proteins.

Interaction Analysis: Detailed interaction profiles will be generated to identify key interactions (e.g., hydrogen bonds, hydrophobic contacts, π-π stacking) contributing to binding stability.[12]

Visualization: Docking poses will be visualized using molecular visualization tools like PyMOL or Chimera to examine the orientation and interactions of ligands within the active sites.

Structure-Activity Relationship (SAR) Studies

SAR Analysis: The relationship between the chemical structure of pyrimidine derivatives and their docking scores/interactions will be examined to identify structural features that enhance antiviral activity.

Feature Identification: Functional groups and substituents that significantly impact binding affinity will be highlighted, guiding the rational design of more potent derivatives.

Identification of Lead Compounds

Lead Selection: Compounds with the highest docking scores and most favourable interaction profiles will be identified as lead candidates.

Prioritization: Lead compounds will be prioritized for further study based on their binding affinities, interaction patterns, and drug-like properties.[13]

Validation and Optimization

Experimental Validation: The most promising lead compounds will be subjected to in vitro antiviral assays to validate their efficacy against specific viruses.

Optimization: Based on experimental results, lead compounds will undergo further optimization to enhance their potency, selectivity, and pharmacokinetic properties.[14]

DOCKING

Molecular docking is a computational technique used to predict how molecules, such as a drug (ligand), interact with a target protein (receptor). It plays a crucial role in drug discovery and development by helping researchers understand the binding modes and affinity between ligands and receptors. Here's an overview of the docking process:[15]

Steps Involved in Molecular Docking

Preparation of Receptor Protein:

Obtain the three-dimensional structure of the target protein (receptor) from databases like the Protein Data Bank (PDB).

Prepare the protein by removing water molecules, adding missing atoms, and assigning charges as needed.[16]

Preparation of Ligand (Drug):

Obtain or generate the three-dimensional structure of the ligand (drug) you want to dock. This can be retrieved from databases or drawn using chemical drawing software.

Optimize the ligand structure and assign charges if necessary. [17]

Grid Generation:

Define a search space or docking grid around the active site of the receptor where the ligand is expected to bind. This helps in focusing the docking simulation on biologically relevant regions of the protein.[18]

Docking Simulation:

Use molecular docking software (e.g., AutoDock, AutoDock Vina, Schrödinger's Glide) to perform the docking simulation.[19]

Docking algorithms calculate the best possible binding orientation and affinity of the ligand within the receptor's active site.

Various scoring functions are used to evaluate the binding energy and predict the strength of ligand-protein interactions.

Analysis of Docking Results

Analyze the docking results to identify the most favourable binding poses (orientations) of the ligand within the receptor.

Evaluate the binding affinity scores and interaction energies to prioritize potential drug candidates.[20]

Visualize the protein-ligand interactions using molecular visualization software (e.g., PyMOL, Chimera) to understand key interactions such as hydrogen bonding, hydrophobic contacts, and electrostatic interactions.

Validation and Optimization:

Validate the docking results by comparing with experimental data or known binding modes, if available.

Optimize the ligand or perform iterative docking simulations to refine the binding poses and enhance binding affinity.[20]

Applications of Molecular Docking

Drug Discovery: Identify and optimize potential drug candidates by predicting their binding affinity and interaction with target proteins.

Virtual Screening: Screen large databases of compounds to identify molecules with potential therapeutic activity against specific targets.

Structure-Activity Relationship (SAR) Studies: Understand how structural modifications affect the binding affinity and activity of ligands.

Biological Insights: Gain insights into the molecular mechanisms of disease and drug action by studying ligand-receptor interactions at the atomic level.[21]

Considerations and Limitations

Scoring Functions: Choice of scoring function can influence the accuracy of docking predictions.

Flexibility: Accounting for protein and ligand flexibility can improve docking accuracy but also increases computational complexity.

Validation: Experimental validation is essential to confirm predicted binding modes and affinity.[21]



Figure No.1: Flow chart of the Process of Molecular Docking

RESULT



Molecule 1



Molecule 2



Molecule 3



Molecule 4

Figure No. 2: Molecules Drawn by Che sketch Software chemical Structure Presentation

Molecules	Code	Wire frame model	Sticks model	Ball and Stick model	Space fill model
1	Py1				
2	Py2				
3	Py3				
4	Py4				

TABLE No.1: Chemical Representation of molecules with the help of BIOVIA Discovery Studio

DISCUSSION

The outcomes of Swiss ADME and Toxicity Predictions are summarized the result presented indicates that all the investigated compounds present a high gastrointestinal absorption, compounds 1 crosses BBB except molecule 2, 3, 4 does not crosses BBB, good skin permeation and they inhibit cytochrome CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4. These predictions are in agreement with few available studies concerning human oral administration conducting to fast on human data. This method provides an easy interpretation of the predicted activity and also allowing the user to easily propose structural modifications, absorption and fast metabolism.

CONCLUSION

We have drawn chemical structure using various software and had calculated various properties like molar volume, molar refractivity, etc., using this software. These structures were also represented in various forms like wireframe, stick, ball & stick, & space filling. Pharmacophore for the structures was prepared using VLife MDS software, and the physicochemical properties of the pharmacophore were obtained from various databases. These molecules were docked on the protein (7nt8; obtained from PDB) using Swiss Dock and molecule 4R was showing highest binding affinity to the protein.

REFERENCES

1. Merz Jr KM, Ringe D, Reynolds CH, editors. Drug design: structure-and ligand-based approaches. Cambridge University Press; 1991 ;373(5):23-30.
2. Castanho M, Santos N, editors. Peptide drug discovery and development: translational research in academia and industry. John Wiley & Sons; 1994 ;345(4):21-24.
3. Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S. Protein–peptide docking: opportunities and challenges. Drug discovery today. 2002; 1:23 (8):150-117.
4. Mahapatra B. Swarm Intelligence and Evolutionary Algorithms for Drug Design and Development. InSwarm Intelligence and Evolutionary Algorithms in Healthcare and Drug Development 2006;455(7) :117-140.
5. Tollenaere JP. The role of structure-based ligand design and molecular modelling in drug discovery. Pharmacy World and Science. 2008 May; 18(2):56-62.
6. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, Pairaudeau G, Pennie WD, Pickett SD, Wang J, Wallace O. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature reviews Drug discovery. 2009; 14(7):475-488.
7. Yu H, Adedoyin A. ADME–Tox in drug discovery: integration of experimental and computational technologies. Drug discovery today. 2009 15; 8(18):852-861.
8. Deore AB, Dhumane JR, Wagh R, Sonawane R. The stages of drug discovery and development process. Asian Journal of Pharmaceutical Research and Development. 2010 15; 7 (6):62-78.
9. Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nature reviews Drug discovery. 2012; 16 (8):531- 643.
10. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. Journal of health economics. 2013; 22 (2):151-185.
11. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug discovery today. 2013; 16 (23-24):1037-1043.
12. Wang DD, Feng LL, He GY, Chen HQ. QSAR studies for the acute toxicity of nitrobenzenes to the Tetrahymena pyriformis. Journal of the Serbian Chemical Society. 2014; 79(9):11-25.
13. Hermens J, Canton H, Janssen P, De Jong R. Quantitative structure-activity relationships and toxicity studies of mixtures of chemicals with anaesthetic potency: Acute lethal and sublethal toxicity to Daphnia magna. Aquatic Toxicology. 2015;5(2):143-154.
14. Van Gestel CA, Ma WC. An approach to quantitative structure-activity relationships (QSARs) in earthworm toxicity studies. Chemosphere. 2015; 21(8):1023-1133.
15. Escher BI, Bramaz N, Richter M, Lienert J. Comparative ecotoxicological hazard assessment of beta-blockers and their human metabolites using a mode-of-action-based test battery and a QSAR approach. Environmental science & technology. 2016 Dec 1;40(23):7402-7528.
16. Zernov VV, Balakin KV, Ivaschenko AA, Savchuk NP, Pletnev IV. Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. Journal of chemical information and computer sciences. 2017; 43(6):2048-2256.
17. Srinivas R. Mane, Sanjay K Bais, Dheeraj D. Dhane perform quality control test for container closures and secondary packing material used in cosmetics IJPHT Journal 2023, 1(3), 196-206.
18. Shrinivas Mane, Sanjay K. Bais, Aditya V. Mali review on green chemistry and catalysis IJPHT Journal,2023, 1(3), 320-329

19. Srinivas R. Mane, Sanjay K Bais, Sandesh S. Akade preparation and evolution of herbal mouthwash IJPHT Journal,2024, 2(1),518-530
20. Shriniwas R. Mane, Sanjay K. Bais, Renuka V. Kshirsagar. an overview on advanced herbal technology IJPHT Journal, 2024, 2(1),887-897